392 related articles for article (PubMed ID: 17764058)
1. Advances in immunosuppressive therapy.
Marder W; McCune WJ
Semin Respir Crit Care Med; 2007 Aug; 28(4):398-417. PubMed ID: 17764058
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy of ab initio immunosuppressive therapy and steroid-sparing effect in interstitial lung disease associated with antisynthetase antibody syndrome].
Franzolini N; Quartuccio L; De Marchi G; De Vita S
Reumatismo; 2007; 59(3):202-8. PubMed ID: 17898879
[TBL] [Abstract][Full Text] [Related]
3. Advances in immunosuppressive drug therapy for use in autoimmune disease and systemic vasculitis.
Marder W; McCune WJ
Semin Respir Crit Care Med; 2004 Oct; 25(5):581-94. PubMed ID: 16088501
[TBL] [Abstract][Full Text] [Related]
4. [Immunosuppressive therapy in clinical practice].
Frey FJ
Schweiz Med Wochenschr; 1987 May; 117(21):810-5. PubMed ID: 3589636
[TBL] [Abstract][Full Text] [Related]
5. Review article: Progress of treatment in ANCA-associated vasculitis.
Jayne D
Nephrology (Carlton); 2009 Feb; 14(1):42-8. PubMed ID: 19335843
[TBL] [Abstract][Full Text] [Related]
6. Immunosuppressive and cytotoxic drugs in the treatment of rheumatic skin disorders.
Callen JP
Semin Cutan Med Surg; 2001 Mar; 20(1):58-68. PubMed ID: 11308138
[TBL] [Abstract][Full Text] [Related]
7. Cyclophosphamide in scleroderma lung disease.
Kuschner WG
N Engl J Med; 2006 Sep; 355(11):1173; author reply 1174. PubMed ID: 16971726
[No Abstract] [Full Text] [Related]
8. Immunosuppressive agents in dermatology.
Ho VC; Zloty DM
Dermatol Clin; 1993 Jan; 11(1):73-85. PubMed ID: 8435920
[TBL] [Abstract][Full Text] [Related]
9. [Wegener's granulomatosis and microscopic polyangiitis].
Pagnoux C
Rev Prat; 2008 Mar; 58(5):522-32. PubMed ID: 18524109
[TBL] [Abstract][Full Text] [Related]
10. [Interstitial pneumonia treated with intermittent cyclophosphamide pulse therapy].
Harada T; Takayama K; Kimotsuki K; Hidaka K; Miyazaki H; Kuwano K; Hara N
Nihon Kyobu Shikkan Gakkai Zasshi; 1996 Nov; 34(11):1221-6. PubMed ID: 8976077
[TBL] [Abstract][Full Text] [Related]
11. Immunosuppressive drug therapy.
McCune WJ; Vallance DK; Lynch JP
Curr Opin Rheumatol; 1994 May; 6(3):262-72. PubMed ID: 8060760
[TBL] [Abstract][Full Text] [Related]
12. Cytogenetic abnormalities and therapy-related myelodysplastic syndromes in rheumatic disease.
McCarthy CJ; Sheldon S; Ross CW; McCune WJ
Arthritis Rheum; 1998 Aug; 41(8):1493-6. PubMed ID: 9704650
[TBL] [Abstract][Full Text] [Related]
13. [New therapeutic strategies in ANCA-associated systemic vasculitis].
Ruiz FL; Bart PA
Rev Med Suisse; 2005 Jan; 1(1):19-23. PubMed ID: 15773192
[TBL] [Abstract][Full Text] [Related]
14. [Strategy of therapy for interstitial lung disease due to chemotherapeutic drugs or radiation].
Ishioka S
Gan To Kagaku Ryoho; 1997 Oct; 24 Suppl 3():432-8. PubMed ID: 9369919
[TBL] [Abstract][Full Text] [Related]
15. Drug therapy. Immunosuppressive agents. I.
Kaplan SR; Calabresi P
N Engl J Med; 1973 Nov; 289(18):952-5. PubMed ID: 4582749
[No Abstract] [Full Text] [Related]
16. Tailoring immunosuppressive therapy in interstitial lung diseases.
Agostini C
Sarcoidosis Vasc Diffuse Lung Dis; 2004 Mar; 21(1):3-9. PubMed ID: 15127968
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous vasculitis: diagnosis and management.
Carlson JA; Cavaliere LF; Grant-Kels JM
Clin Dermatol; 2006; 24(5):414-29. PubMed ID: 16966021
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study.
Bérezné A; Ranque B; Valeyre D; Brauner M; Allanore Y; Launay D; Le Guern V; Kahn JE; Couderc LJ; Constans J; Cohen P; Mahr A; Pagnoux C; Hachulla E; Kahan A; Cabane J; Guillevin L; Mouthon L
J Rheumatol; 2008 Jun; 35(6):1064-72. PubMed ID: 18464307
[TBL] [Abstract][Full Text] [Related]
19. Cyclophosphamide in scleroderma lung disease.
Sullivan KM; McSweeney PA; Nash RA
N Engl J Med; 2006 Sep; 355(11):1173-4; author reply 1174. PubMed ID: 16977701
[No Abstract] [Full Text] [Related]
20. Interstitial lung disease associated with systemic sclerosis: what is the evidence for efficacy of cyclophosphamide?
Bérezné A; Valeyre D; Ranque B; Guillevin L; Mouthon L
Ann N Y Acad Sci; 2007 Sep; 1110():271-84. PubMed ID: 17911442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
